Bioharvest Sciences INC. Delivers a Milestone in the Scale-up Process of Its Cannabis Development Program

VANCOUVER, BC and REHOVOT, Israel, — BioHarvest Sciences Inc. (CSE: BHSC) announced that it has successfully scaled its Cannabis cells with trichomes production by a factor of 250x and it is now growing Cannabis in medium-scale bioreactors, paving the way for its next scale-up milestone, where it will reach industrial-scale production. The next milestone, combined with the drying and measurement standards being concurrently developed, would constitute the successful completion of the Company’s Cannabis development program.

Moving to the medium-scale bioreactors stage is not only a critical milestone in the scale-up and the proof of the capability of the BioFarming technology to produce Cannabis biomass, but is also an integral part of the industrial process development itself. The next milestone of the development program is growing Cannabis trichomes in industrial size bioreactors.

“The R&D methodology and relentless efforts are paying off,” said Dr. Yochi Hagay, CTO, and added, “We are happy to have reached such a critical milestone. The recently announced and proprietary development of the Amalgamated Trichomes Coral Structure (ATCS) has certainly enabled this scale-up progress. As described before, ATCS protects the Trichomes during the growth phase against the shear forces generated by the media fluid motion. Such motion is exacerbated as you increase the size of the bioreactor, and I am confident that ATCS will sustain the forces in the next size of bioreactors, which is the final industrial-scale step. I look forward to announcing the completion of the whole program soon.”

The CEO, Ilan Sobel, said, “Our industry-leading plant cell biology team is on track to deliver on one of the most challenging plant biological missions of growing cells of Cannabis Trichomes in liquid media at an industrial scale. Completing this mission will pave the way to the commercialization of BioFarming based Cannabis and Hemp products, marking a major turning point for the mainstream adoption of Cannabis by the global food and health sectors. The ability to economically and sustainably produce consistent, clean and pure whole spectrum Cannabis is nothing short of a revolution for the industry.”

Eitan Popper, Chairman of BHSC’s board of advisors and former President and Co-Founder of MedReleaf, stated, “BHSC’s R&D team is making meaningful progress every month in the commercial scale-up of their Cannabis production. It is important to note that the most challenging part of the scale-up process is the transition from lab/bench scale to small-scale bioreactors, and then to medium-scale bioreactors. We are eagerly looking forward to the next Cannabis milestone announcement, as we know that it will be meaningful.”

Forward-Looking Statements

Information set forth in this news release includes might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance the company will be able to successfully grow trichomes in industrial size bioreactor.

There is no assurance we will be able to commercialize our first Cannabis products in the first half of 2022. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in demonstrating its ability to consistently grow in solution trichomes from multiple plant strains is not an assurance that the Company will be able to commence commercial production when anticipated or at all. While the Company is in the process of constructing a two-ton production facility the Company‘s current licensing only permits scientific research. Projected sales of Cannabis will require the Company to obtain production and or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

(This information is primarily sourced from BioHarvest Sciences Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).